{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:45:31Z","timestamp":1790520331957,"version":"4.1.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002635","name":"Inha University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 AR063043"],"award-info":[{"award-number":["P50 AR063043"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00223-018-0401-9","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T09:38:57Z","timestamp":1519292337000},"page":"607-618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Osteoporosis in Rheumatic Diseases: Anti-rheumatic Drugs and the Skeleton"],"prefix":"10.1007","volume":"102","author":[{"given":"Alanna M.","family":"Dubrovsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7405-8139","authenticated-orcid":false,"given":"Mie Jin","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy E.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"issue":"Suppl 12","key":"401_CR1","first-page":"S21","volume":"13","author":"J Dequeker","year":"1995","unstructured":"Dequeker J, Maenaut K, Verwilghen J, Westhovens R (1995) Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol 13(Suppl 12):S21\u2013S26","journal-title":"Clin Exp Rheumatol"},{"key":"401_CR2","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S0140-6736(89)92932-2","volume":"2","author":"R Will","year":"1989","unstructured":"Will R, Palmer R, Bhalla AK, Ring F, Calin A (1989) Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet 2:1483\u20131485","journal-title":"Lancet"},{"key":"401_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/bmj.300.6724.563","volume":"300","author":"SH Ralston","year":"1990","unstructured":"Ralston SH, Urquhart GD, Brzeski M, Sturrock RD (1990) Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. BMJ 300:563\u2013565","journal-title":"BMJ"},{"key":"401_CR4","doi-asserted-by":"publisher","first-page":"R154","DOI":"10.1186\/ar3107","volume":"12","author":"SY Kim","year":"2010","unstructured":"Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang CL, Garneau K, Solomon DH (2010) Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther 12:R154","journal-title":"Arthritis Res Ther"},{"key":"401_CR5","doi-asserted-by":"publisher","first-page":"e6983","DOI":"10.1097\/MD.0000000000006983","volume":"96","author":"AL Xue","year":"2017","unstructured":"Xue AL, Wu SY, Jiang L, Feng AM, Guo HF, Zhao P (2017) Bone fracture risk in patients with rheumatoid arthritis: a meta-analysis. Medicine 96:e6983","journal-title":"Medicine"},{"key":"401_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/BOR.0b013e3283620777","volume":"25","author":"N Davey-Ranasinghe","year":"2013","unstructured":"Davey-Ranasinghe N, Deodhar A (2013) Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 25:509\u2013516","journal-title":"Curr Opin Rheumatol"},{"key":"401_CR7","doi-asserted-by":"crossref","unstructured":"Paine A, Ritchlin C (2018) Altered bone remodeling in psoriatic disease: new insights and future directions. Calcif Tissue Int 1\u201316","DOI":"10.1007\/s00223-017-0380-2"},{"key":"401_CR8","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1007\/s00198-013-2334-5","volume":"24","author":"M Vis","year":"2013","unstructured":"Vis M, Guler-Yuksel M, Lems WF (2013) Can bone loss in rheumatoid arthritis be prevented? Osteoporos Int 24:2541\u20132553","journal-title":"Osteoporos Int"},{"key":"401_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/ar3375","volume":"13","author":"P Geusens","year":"2011","unstructured":"Geusens P, Lems WF (2011) Osteoimmunology and osteoporosis. Arthritis Res Ther 13:242","journal-title":"Arthritis Res Ther"},{"key":"401_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/1759720X12438080","volume":"4","author":"P Geusens","year":"2012","unstructured":"Geusens P (2012) The role of RANK ligand\/osteoprotegerin in rheumatoid arthritis. Ther Adv Musculoskelet Dis 4:225\u2013233","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"401_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156\u2013163","journal-title":"Nat Med"},{"key":"401_CR12","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/1529-0131(200003)43:3<522::AID-ANR7>3.0.CO;2-Y","volume":"43","author":"G Haugeberg","year":"2000","unstructured":"Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 43:522\u2013530","journal-title":"Arthritis Rheum"},{"key":"401_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385\u2013397","journal-title":"Osteoporos Int"},{"key":"401_CR14","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00198-010-1462-4","volume":"22","author":"CB Confavreux","year":"2011","unstructured":"Confavreux CB, Chapurlat RD (2011) Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis. Osteoporos Int 22:1023\u20131036","journal-title":"Osteoporos Int"},{"key":"401_CR15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/rheumatology\/kes369","volume":"52","author":"IL Engvall","year":"2013","unstructured":"Engvall IL, Svensson B, Boonen A, van der Heijde D, Lerner UH, Hafstrom I (2013) Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP: a possible mechanism for specific inhibition of radiological destruction. Rheumatology 52:733\u2013742","journal-title":"Rheumatology"},{"key":"401_CR16","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1002\/art.23454","volume":"58","author":"W Yao","year":"2008","unstructured":"Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE (2008) Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 58:1674\u20131686","journal-title":"Arthritis Rheum"},{"key":"401_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00198-016-3769-2","volume":"28","author":"CAF Zerbini","year":"2017","unstructured":"Zerbini CAF, Clark P, Mendez-Sanchez L, Pereira RMR, Messina OD, Una CR, Adachi JD, Lems WF, Cooper C, Lane NE (2017) Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int 28:429\u2013446","journal-title":"Osteoporos Int"},{"key":"401_CR18","doi-asserted-by":"publisher","first-page":"ii56-ii60","DOI":"10.1093\/rheumatology\/kew345","volume":"55","author":"SR Goldring","year":"2016","unstructured":"Goldring SR (2016) Differential mechanisms of de-regulated bone formation in rheumatoid arthritis and spondyloarthritis. Rheumatology 55:ii56-ii60","journal-title":"Rheumatology"},{"key":"401_CR19","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","volume":"8","author":"DA Glass 2nd","year":"2005","unstructured":"Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751\u2013764","journal-title":"Dev Cell"},{"key":"401_CR20","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/jcp.26028","volume":"233","author":"T Both","year":"2018","unstructured":"Both T, Zillikens MC, Schreuders-Koedam M, Vis M, Lam WK, Weel A, van Leeuwen J, van Hagen PM, van der Eerden BCJ, van Daele PLA (2018) Hydroxychloroquine affects bone resorption both in vitro and in vivo. J Cell Physiol 233:1424\u20131433","journal-title":"J Cell Physiol"},{"key":"401_CR21","first-page":"2299","volume":"29","author":"B Tengstrand","year":"2002","unstructured":"Tengstrand B, Hafstrom I (2002) Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. J Rheumatol 29:2299\u20132305","journal-title":"J Rheumatol"},{"key":"401_CR22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00296-008-0682-9","volume":"29","author":"A Pfeil","year":"2009","unstructured":"Pfeil A, Lippold J, Eidner T, Lehmann G, Oelzner P, Renz DM, Hansch A, Wolf G, Hein G, Kaiser WA, Bottcher J (2009) Effects of leflunomide and methotrexate in rheumatoid arthritis detected by digital X-ray radiogrammetry and computer-aided joint space analysis. Rheumatol Int 29:287\u2013295","journal-title":"Rheumatol Int"},{"key":"401_CR23","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/sj.leu.2402078","volume":"15","author":"SC Kaste","year":"2001","unstructured":"Kaste SC, Jones-Wallace D, Rose SR, Boyett JM, Lustig RH, Rivera GK, Pui CH, Hudson MM (2001) Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia 15:728\u2013734","journal-title":"Leukemia"},{"key":"401_CR24","first-page":"1305","volume":"31","author":"O di Munno","year":"2004","unstructured":"di Munno O, Mazzantini M, Sinigaglia L, Bianchi G, Minisola G, Muratore M, la Corte R, di Matteo L, Canesi B, Caminiti M, Broggini M, Adami S (2004) Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. J Rheumatol 31:1305\u20131309","journal-title":"J Rheumatol"},{"key":"401_CR25","first-page":"2395","volume":"28","author":"AB Cranney","year":"2001","unstructured":"Cranney AB, McKendry RJ, Wells GA, Ooi DS, Kanigsberg ND, Kraag GR, Smith CD (2001) The effect of low dose methotrexate on bone density. J Rheumatol 28:2395\u20132399","journal-title":"J Rheumatol"},{"key":"401_CR26","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/rheumatology\/41.7.741","volume":"41","author":"NJ Minaur","year":"2002","unstructured":"Minaur NJ, Kounali D, Vedi S, Compston JE, Beresford JN, Bhalla AK (2002) Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology 41:741\u2013749","journal-title":"Rheumatology"},{"key":"401_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00296-003-0298-z","volume":"23","author":"F Tascioglu","year":"2003","unstructured":"Tascioglu F, Oner C, Armagan O (2003) The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis. Rheumatol Int 23:231\u2013235","journal-title":"Rheumatol Int"},{"key":"401_CR28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s002239900585","volume":"64","author":"LD Carbone","year":"1999","unstructured":"Carbone LD, Kaeley G, McKown KM, Cremer M, Palmieri G, Kaplan S (1999) Effects of long-term administration of methotrexate on bone mineral density in rheumatoid arthritis. Calcif Tissue Int 64:100\u2013101","journal-title":"Calcif Tissue Int"},{"key":"401_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s001980050189","volume":"10","author":"ML Bianchi","year":"1999","unstructured":"Bianchi ML, Cimaz R, Galbiati E, Corona F, Cherubini R, Bardare M (1999) Bone mass change during methotrexate treatment in patients with juvenile rheumatoid arthritis. Osteoporos Int 10:20\u201325","journal-title":"Osteoporos Int"},{"key":"401_CR30","first-page":"1489","volume":"24","author":"LM Buckley","year":"1997","unstructured":"Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1997) Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 24:1489\u20131494","journal-title":"J Rheumatol"},{"key":"401_CR31","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3109\/s10165-006-0517-z","volume":"16","author":"E Torikai","year":"2006","unstructured":"Torikai E, Kageyama Y, Takahashi M, Nagano A (2006) The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis. Mod Rheumatol 16:350\u2013354","journal-title":"Mod Rheumatol"},{"key":"401_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5455\/medarh.2016.70.101-103","volume":"70","author":"S Rexhepi","year":"2016","unstructured":"Rexhepi S, Rexhepi M, Sahatciu-Meka V, Mahmutaj V, Boshnjaku S (2016) The impact of low-dose disease-modifying anti-rheumatics drugs (DMARDs) on bone mineral density of premenopausal women in early rheumatoid arthritis. Med Arch 70:101\u2013103","journal-title":"Med Arch"},{"key":"401_CR33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s00774-005-0657-9","volume":"24","author":"K Arai","year":"2006","unstructured":"Arai K, Hanyu T, Sugitani H, Murai T, Fujisawa J, Nakazono K, Kondo N, Endo N (2006) Risk factors for vertebral fracture in menopausal or postmenopausal Japanese women with rheumatoid arthritis: a cross-sectional and longitudinal study. J Bone Mineral Metab 24:118\u2013124","journal-title":"J Bone Mineral Metab"},{"key":"401_CR34","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.bone.2004.07.004","volume":"35","author":"N Saidenberg-Kermanac\u2019h","year":"2004","unstructured":"Saidenberg-Kermanac\u2019h N, Corrado A, Lemeiter D, deVernejoul MC, Boissier MC, Cohen-Solal ME (2004) TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35:1200\u20131207","journal-title":"Bone"},{"key":"401_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3349\/ymj.2013.54.1.183","volume":"54","author":"I Korczowska","year":"2013","unstructured":"Korczowska I, Lacki JK, Hrycaj P (2013) Influence of infliximab on cytokines network and markers of bone remodeling in rheumatoid arthritis patients. Yonsei Med J 54:183\u2013188","journal-title":"Yonsei Med J"},{"key":"401_CR36","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/ard.2007.076604","volume":"67","author":"F Chopin","year":"2008","unstructured":"Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T (2008) Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 67:353\u2013357","journal-title":"Ann Rheum Dis"},{"key":"401_CR37","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1002\/art.11292","volume":"48","author":"M Vis","year":"2003","unstructured":"Vis M, Wolbink GJ, Lodder MC, Kostense PJ, van de Stadt RJ, de Koning MH, Dijkmans BA, Lems WF (2003) Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. Arthritis Rheum 48:2996\u20132997","journal-title":"Arthritis Rheum"},{"key":"401_CR38","doi-asserted-by":"publisher","first-page":"R61","DOI":"10.1186\/ar2219","volume":"9","author":"H Marotte","year":"2007","unstructured":"Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P (2007) A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 9:R61","journal-title":"Arthritis Res Ther"},{"key":"401_CR39","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1136\/ard.2005.044198","volume":"65","author":"M Vis","year":"2006","unstructured":"Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, Dijkmans BA, Woolf AD, Kvien TK, Lems WF (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495\u20131499","journal-title":"Ann Rheum Dis"},{"key":"401_CR40","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/rheumatology\/kei082","volume":"44","author":"U Lange","year":"2005","unstructured":"Lange U, Teichmann J, Muller-Ladner U, Strunk J (2005) Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology 44:1546\u20131548","journal-title":"Rheumatology"},{"key":"401_CR41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/ard.2008.091611","volume":"68","author":"CA Wijbrandts","year":"2009","unstructured":"Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP (2009) Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 68:373\u2013376","journal-title":"Ann Rheum Dis"},{"key":"401_CR42","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1136\/ard.2003.017780","volume":"64","author":"M Vis","year":"2005","unstructured":"Vis M, Voskuyl AE, Wolbink GJ, Dijkmans BA, Lems WF (2005) Bone mineral density in patients with rheumatoid arthritis treated with infliximab. Ann Rheum Dis 64:336\u2013337","journal-title":"Ann Rheum Dis"},{"key":"401_CR43","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/ard.2007.073817","volume":"67","author":"M Guler-Yuksel","year":"2008","unstructured":"Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Hulsmans HM, de Beus WM, Han KH, Breedveld FC, Dijkmans BA, Allaart CF, Lems WF (2008) Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 67:823\u2013828","journal-title":"Ann Rheum Dis"},{"key":"401_CR44","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/ard.2009.127787","volume":"70","author":"DA Eekman","year":"2011","unstructured":"Eekman DA, Vis M, Bultink IE, Kuik DJ, Voskuyl AE, Dijkmans BA, Lems WF (2011) Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:389\u2013390","journal-title":"Ann Rheum Dis"},{"key":"401_CR45","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/rheumatology\/kes320","volume":"52","author":"CL Krieckaert","year":"2013","unstructured":"Krieckaert CL, Nurmohamed MT, Wolbink G, Lems WF (2013) Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology 52:547\u2013553","journal-title":"Rheumatology"},{"key":"401_CR46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/art.25053","volume":"62","author":"P Garnero","year":"2010","unstructured":"Garnero P, Thompson E, Woodworth T, Smolen JS (2010) Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 62:33\u201343","journal-title":"Arthritis Rheum"},{"key":"401_CR47","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.semarthrit.2012.01.004","volume":"42","author":"MA Karsdal","year":"2012","unstructured":"Karsdal MA, Schett G, Emery P, Harari O, Byrjalsen I, Kenwright A, Bay-Jensen AC, Platt A (2012) IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin Arthritis Rheum 42:131\u2013139","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"401_CR48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jbspin.2014.10.015","volume":"82","author":"K Briott","year":"2015","unstructured":"Briott K, Rouanet S, Schaeverbeke T, Etchepare F, Gaudin P, Perdriger A, Vray M, Steinberg G, Roux C (2015) The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis. Joint Bone Spine 82(2):109\u2013115","journal-title":"Joint Bone Spine"},{"key":"401_CR49","doi-asserted-by":"publisher","first-page":"e0188454","DOI":"10.1371\/journal.pone.0188454","volume":"12","author":"YM Chen","year":"2017","unstructured":"Chen YM, Chen HH, Huang WN, Liao TL, Chen JP, Chao WC, Lin CT, Hung WT, Hsieh CW, Hsieh TY, Chen YH, Chen DY (2017) Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis. PLoS ONE 12:e0188454","journal-title":"PLoS ONE"},{"key":"401_CR50","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/rheumatology\/ket468","volume":"53","author":"K Kume","year":"2014","unstructured":"Kume K, Amano K, Yamada S, Kanazawa T, Ohta H, Hatta K, Amano K, Kuwaba N (2014) The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis. Rheumatology 53:900\u2013903","journal-title":"Rheumatology"},{"key":"401_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-9255-7-41","volume":"7","author":"DM Meyer","year":"2010","unstructured":"Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK, Hirsch JL, Saabye MJ, Barks JL, Kishore N, Morris DL (2010) Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm 7:41","journal-title":"J Inflamm"},{"key":"401_CR52","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377\u20132386","journal-title":"N Engl J Med"},{"key":"401_CR53","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzova D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD, Connell CA (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65:559\u2013570","journal-title":"Arthritis Rheum"},{"key":"401_CR54","doi-asserted-by":"crossref","unstructured":"Vidal B, Cascao R, Finnila MAJ, Lopes IP, da Gloria VG, Saarakkala S, Zioupos P, Canhao H, Fonseca JE (2017) Effects of tofacitinib in early arthritis-induced bone loss in an adjuvant-induced arthritis rat model. Rheumatology","DOI":"10.1136\/annrheumdis-2017-eular.3491"},{"key":"401_CR55","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1359\/jbmr.090724","volume":"25","author":"XD Chen","year":"2010","unstructured":"Chen XD, Xiao P, Lei SF, Liu YZ, Guo YF, Deng FY, Tan LJ, Zhu XZ, Chen FR, Recker RR, Deng HW (2010) Gene expression profiling in monocytes and SNP association suggest the importance of the STAT1 gene for osteoporosis in both Chinese and Caucasians. J Bone Mineral Res 25:339\u2013355","journal-title":"J Bone Mineral Res"},{"key":"401_CR56","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.bone.2011.04.020","volume":"49","author":"H Zhou","year":"2011","unstructured":"Zhou H, Newnum AB, Martin JR, Li P, Nelson MT, Moh A, Fu XY, Yokota H, Li J (2011) Osteoblast\/osteocyte-specific inactivation of Stat3 decreases load-driven bone formation and accumulates reactive oxygen species. Bone 49:404\u2013411","journal-title":"Bone"},{"key":"401_CR57","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00296-010-1560-9","volume":"31","author":"G Hein","year":"2011","unstructured":"Hein G, Eidner T, Oelzner P, Rose M, Wilke A, Wolf G, Franke S (2011) Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study. Rheumatol Int 31:269\u2013272","journal-title":"Rheumatol Int"},{"key":"401_CR58","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/annrheumdis-2011-200198","volume":"71","author":"MJ Boumans","year":"2012","unstructured":"Boumans MJ, Thurlings RM, Yeo L, Scheel-Toellner D, Vos K, Gerlag DM, Tak PP (2012) Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann Rheum Dis 71:108\u2013113","journal-title":"Ann Rheum Dis"},{"key":"401_CR59","first-page":"704","volume":"69","author":"SQI Salvin","year":"2010","unstructured":"Salvin SQI, Master M, Corazza I, De Marchi G, Lombardi S et al (2010) Variations in lumbar spine and femoral BMD after rituximab therapy in active rheumatoid arthritis. Ann Rheum Dis 69:704","journal-title":"Ann Rheum Dis"},{"key":"401_CR60","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1136\/ard.2007.080713","volume":"67","author":"R Axmann","year":"2008","unstructured":"Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, Herrmann M, Smolen J, Schett G (2008) CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 67:1603\u20131609","journal-title":"Ann Rheum Dis"},{"key":"401_CR61","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/annrheumdis-2015-eular.2214","volume":"74","author":"M Tada","year":"2015","unstructured":"Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Koike T, Nakamura H (2015) FRI0062 influence of biologic agents on bone mineral density and bone mineral markers in patients with rheumatoid arthritis: data from the airtight study. Ann Rheum Dis 74:441\u2013442","journal-title":"Ann Rheum Dis"},{"key":"401_CR62","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00223-017-0274-3","volume":"101","author":"C Pray","year":"2017","unstructured":"Pray C, Feroz NI, Nigil Haroon N (2017) Bone mineral density and fracture risk in ankylosing spondylitis: a meta-analysis. Calcif Tissue Int 101:182\u2013192","journal-title":"Calcif Tissue Int"},{"key":"401_CR63","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, Lin SL, Tsuji W, Davis JC Jr (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58:1324\u20131331","journal-title":"Arthritis Rheum"},{"key":"401_CR64","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, Gorman DM, Bowman EP, McClanahan TK, Yearley JH, Eberl G, Buckley CD, Kastelein RA, Pierce RH, Laface DM, Cua DJ (2012) IL-23 induces spondyloarthropathy by acting on ROR-gammat + CD3 + CD4-CD8- entheseal resident T cells. Nat Med 18:1069\u20131076","journal-title":"Nat Med"},{"key":"401_CR65","first-page":"488","volume":"56","author":"AA El-Zayadi","year":"2017","unstructured":"El-Zayadi AA, Jones EA, Churchman SM, Baboolal TG, Cuthbert RJ, El-Jawhari JJ, Badawy AM, Alase AA, El-Sherbiny YM, McGonagle D (2017) Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies. Rheumatology 56:488\u2013493","journal-title":"Rheumatology"},{"key":"401_CR66","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.berh.2014.10.008","volume":"28","author":"RJ Lories","year":"2014","unstructured":"Lories RJ, Haroon N (2014) Bone formation in axial spondyloarthritis. Best Pract Res Clin Rheumatol 28:765\u2013777","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"401_CR67","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","volume":"43","author":"J Brandt","year":"2000","unstructured":"Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346\u20131352","journal-title":"Arthritis Rheum"},{"key":"401_CR68","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/ard.62.4.347","volume":"62","author":"F Allali","year":"2003","unstructured":"Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C (2003) Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 62:347\u2013349","journal-title":"Ann Rheum Dis"},{"key":"401_CR69","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/ard.2007.084426","volume":"68","author":"S Visvanathan","year":"2009","unstructured":"Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J, Braun J (2009) Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 68:175\u2013182","journal-title":"Ann Rheum Dis"},{"key":"401_CR70","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jbspin.2010.05.010","volume":"78","author":"KY Kang","year":"2011","unstructured":"Kang KY, Lee KY, Kwok SK, Ju JH, Park KS, Hong YS, Kim HY, Park SH (2011) The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis. Joint Bone Spine 78:188\u2013193","journal-title":"Joint Bone Spine"},{"key":"401_CR71","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.autrev.2017.01.014","volume":"16","author":"A Szentpetery","year":"2017","unstructured":"Szentpetery A, Horvath A, Gulyas K, Petho Z, Bhattoa HP, Szanto S, Szucs G, FitzGerald O, Schett G, Szekanecz Z (2017) Effects of targeted therapies on the bone in arthritides. Autoimmun Rev 16:313\u2013320","journal-title":"Autoimmun Rev"},{"key":"401_CR72","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/jcm6070073","volume":"6","author":"M Hashimoto","year":"2017","unstructured":"Hashimoto M (2017) Th17 in animal models of rheumatoid arthritis. J Clin Med 6:73","journal-title":"J Clin Med"},{"key":"401_CR73","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1084\/jem.20061775","volume":"203","author":"K Sato","year":"2006","unstructured":"Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673\u20132682","journal-title":"J Exp Med"},{"key":"401_CR74","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","volume":"19","author":"K Pavelka","year":"2017","unstructured":"Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Pricop L, Andersson M, Readie A, Porter B (2017) Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther 19:285","journal-title":"Arthritis Res Ther"},{"key":"401_CR75","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewe R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382:1705\u20131713","journal-title":"Lancet"},{"key":"401_CR76","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373:2534\u20132548","journal-title":"N Engl J Med"},{"key":"401_CR77","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/1346-8138.12546","volume":"41","author":"S D\u2019Epiro","year":"2014","unstructured":"D\u2019Epiro S, Marocco C, Salvi M, Mattozzi C, Luci C, Macaluso L, Giancristoforo S, Campoli M, Scarno M, Migliaccio S, Calvieri S, Richetta A (2014) Psoriasis and bone mineral density: implications for long-term patients. J Dermatol 41:783\u2013787","journal-title":"J Dermatol"},{"key":"401_CR78","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.reuma.2013.07.006","volume":"10","author":"N Busquets","year":"2014","unstructured":"Busquets N, Vaquero CG, Moreno JR, Vilaseca DR, Narvaez J, Carmona L, Nolla JM (2014) Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital. Reumatol Clin 10:89\u201393","journal-title":"Reumatol Clin"},{"key":"401_CR79","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, Zeidler H, Dougados M (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52:1756\u20131765","journal-title":"Arthritis Rheum"},{"key":"401_CR80","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780\u2013789","journal-title":"Lancet"},{"key":"401_CR81","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C, Hough D, Stevens RM, Schett G (2014) Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73:1020\u20131026","journal-title":"Ann Rheum Dis"},{"key":"401_CR82","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB (2014) Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73:990\u2013999","journal-title":"Ann Rheum Dis"},{"key":"401_CR83","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewe R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S (2015) Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med 373:1329\u20131339","journal-title":"N Engl J Med"},{"key":"401_CR84","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/art.39685","volume":"68","author":"D van der Heijde","year":"2016","unstructured":"van der Heijde D, Landewe RB, Mease PJ, McInnes IB, Conaghan PG, Pricop L, Ligozio G, Richards HB, Mpofu S (2016) Brief Report: secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheumatol 68:1914\u20131921","journal-title":"Arthritis Rheumatol"},{"key":"401_CR85","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1002\/art.21824","volume":"54","author":"SJ Jarrett","year":"2006","unstructured":"Jarrett SJ, Conaghan PG, Sloan VS, Papanastasiou P, Ortmann CE, O\u2019Connor PJ, Grainger AJ, Emery P (2006) Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 54:1410\u20131414","journal-title":"Arthritis Rheum"},{"key":"401_CR86","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/ard.2010.142539","volume":"70","author":"F McQueen","year":"2011","unstructured":"McQueen F, Lloyd R, Doyle A, Robinson E, Lobo M, Exeter M, Taylor WJ, Jones P, Reid IR, Dalbeth N (2011) Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the zoledronic acid in psoriatic arthritis (ZAPA) Study. Ann Rheum Dis 70:1091\u20131094","journal-title":"Ann Rheum Dis"},{"key":"401_CR87","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ecl.2016.11.001","volume":"46","author":"L Bandeira","year":"2017","unstructured":"Bandeira L, Bilezikian JP (2017) Novel therapies for postmenopausal osteoporosis. Endocrinol Metab Clin North Am 46:207\u2013219","journal-title":"Endocrinol Metab Clin North Am"},{"key":"401_CR88","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1136\/ard.2009.112920","volume":"69","author":"RK Dore","year":"2010","unstructured":"Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, Wang H, Tsuji W, Newmark R (2010) Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 69:872\u2013875","journal-title":"Ann Rheum Dis"},{"key":"401_CR89","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/acr.23133","volume":"69","author":"J Yue","year":"2017","unstructured":"Yue J, Griffith JF, Xiao F, Shi L, Wang D, Shen J, Wong P, Li EK, Li M, Li TK, Zhu TY, Hung VW, Qin L, Tam LS (2017) Repair of bone erosion in rheumatoid arthritis by denosumab: a high-resolution peripheral quantitative computed tomography study. Arthritis Care Res 69:1156\u20131163","journal-title":"Arthritis Care Res"},{"key":"401_CR90","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/annrheumdis-2015-208052","volume":"75","author":"T Takeuchi","year":"2016","unstructured":"Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T, Okubo N, Genant HK, van der Heijde D (2016) Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis 75:983\u2013990","journal-title":"Ann Rheum Dis"},{"key":"401_CR91","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/art.23417","volume":"58","author":"SB Cohen","year":"2008","unstructured":"Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58:1299\u20131309","journal-title":"Arthritis Rheum"},{"key":"401_CR92","doi-asserted-by":"crossref","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, Roux C, Torring O, Valter I, Wang AT, Brown JP (2017) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Mineral Res","DOI":"10.1002\/jbmr.3337"},{"key":"401_CR93","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMra067395","volume":"357","author":"E Canalis","year":"2007","unstructured":"Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905\u2013916","journal-title":"N Engl J Med"},{"key":"401_CR94","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1172\/JCI3914","volume":"102","author":"NE Lane","year":"1998","unstructured":"Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD (1998) Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627\u20131633","journal-title":"J Clin Invest"},{"key":"401_CR95","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028\u20132039","journal-title":"N Engl J Med"},{"key":"401_CR96","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jbmr.1870","volume":"28","author":"CC Gluer","year":"2013","unstructured":"Gluer CC, Marin F, Ringe JD, Hawkins F, Moricke R, Papaioannu N, Farahmand P, Minisola S, Martinez G, Nolla JM, Niedhart C, Guanabens N, Nuti R, Martin-Mola E, Thomasius F, Kapetanos G, Pena J, Graeff C, Petto H, Sanz B, Reisinger A, Zysset PK (2013) Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Mineral Res 28:1355\u20131368","journal-title":"J Bone Mineral Res"},{"key":"401_CR97","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1007\/s00198-014-2819-x","volume":"25","author":"K Ebina","year":"2014","unstructured":"Ebina K, Hashimoto J, Shi K, Kashii M, Hirao M, Yoshikawa H (2014) Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients. Osteoporos Int 25:2755\u20132765","journal-title":"Osteoporos Int"},{"key":"401_CR98","first-page":"363","volume":"16","author":"A Migliore","year":"2012","unstructured":"Migliore A, Massafra U, Bizzi E, Argento G, Diamanti AP, Germano V, Tormenta S, Arduini F, Iannessi F, Granatas M, Lagana B (2012) May etanercept and PTH (1\u201334) association heal erosions in early rheumatoid arthritis? A pilot study. Eur Rev Med Pharmacol Sci 16:363\u2013369","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"401_CR99","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/art.40156","volume":"69","author":"DH Solomon","year":"2017","unstructured":"Solomon DH, Kay J, Duryea J, Lu B, Bolster MB, Yood RA, Han R, Ball S, Coleman C, Lo E, Wohlfahrt A, Sury M, Yin M, Yu Z, Zak A, Gravallese EM (2017) Effects of teriparatide on joint erosions in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol 69:1741\u20131750","journal-title":"Arthritis Rheumatol"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-018-0401-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-018-0401-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-018-0401-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T05:31:57Z","timestamp":1589693517000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-018-0401-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1007\/s00223-018-0401-9","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]},"assertion":[{"value":"27 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Alanna M. Dubrovsky, Mie Jin Lim, Nancy E. Lane have no conflicts of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"There were no human or animal studies that were performed by the authors that were described in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}